This program aims to develop anti-B7-H4 × CD3 therapeutic Bispecific Antibody for immuno-oncology.
B7 homolog 4 (B7-H4, VTCN1) acts as a negative regulator of the immune response and overexpressed in many human cancers, suggesting that B7-H4 may be a potential target for cancer therapy. The expression of B7-H4 is reported to be affected by the tumor microenvironment. Studies have also shown that anti-human B7-H4 monoclonal antibodies do not inhibit the growth of positive breast tumors in the mouse model, because of the molecular instability. Thus, B7-H4 Bispecific Antibody is becoming a more promising research strategy for cancer immunotherapy.
The CD3 (cluster of differentiation 3) T cell co-receptor is composed of four distinct chains that bind to T cell receptor (TCR) and ζ-chain (ζ-chain) in T lymphocytes to generate an activation signal. In particular, the co-receptor helps to activate cytotoxic T cells (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
B7-H4 (VTCN1) is a member of the CD28/B7 family of immune co-inhibitory molecules, which can inhibit CD4+ and CD8+ T-cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-lymphocytes (CTLs) by arresting the cell cycle. Multiple studies have found that:
Fig.1 The mechanistic action of B7-H4 in tumor immunity.
To the best of our knowledge, less research has been done on B7-H4 Bispecific Antibody in the field of cancer immunotherapy. Here, we present the latest data about B7-H4 Bispecific Antibody work as a potential target for cancer immunotherapy, which published in 2019.
(Clinical Cancer Research, 2019)
Based on the published data, B7-H4 has a limited expression in normal peripheral tissues, such as lung epithelium, whereas it is expressed at higher levels in several human cancers, particularly in breast carcinomas and lung malignancies. Therefore, we intend to develop multiple programs for different indications (not limited to one specific tumor type), in which B7-H4 is highly expressed.
Currently, there are NO clinical studies working on this novel combination therapy. Our program will be the pioneer in the field. While our program focus on CD3 Bispecific Antibody antibodies, future efforts will develop simultaneous multiple interaction T-cell engaging (SMITE) bispecific pairs targeting other co-receptor signaling pathways. In this case, we are incredibly excited about this program and will try our best to make the dual targeting method clinically feasible.
With extensive experience in providing CRO services, we are confident in providing a streamlined end-to-end program. For each program, we are committed to developing a complete program that tailors to the needs of our partners, from antibody discovery, engineering, optimization, to pre-clinical studies. Periodic progress will be delivered to our clients for effective, smooth and timely communications.
Creative Biolabs is looking for potential partners (include but not limited major pharma or biotech firms) to develop anti-B7-H4 × CD3 bispecific antibody program together. Our scientists are dedicated to bringing together years of valuable experience to our partner and achieve a meaningful partnership. By using this strategic collaboration, we hope to help both parties to proceed with IND and many stages of clinical trials beyond.
If you are interested in our program, please feel free to contact us to learn more details about the cooperation. Looking forward to working with you in the near future.
For Research Use Only | Not For Clinical Use
Download our brochure